Preoperative prostate biopsy and multiparametric magnetic resonance imaging: Reliability in detecting prostate cancer - Abstract

PURPOSE: The aim of the study was to analyse and compare the ability of multiparametric magnetic resonance imaging (mp-MRI) and prostate biopsy (PB) to correctly identify tumor foci in patients undergoing radical prostatectomy (RP) for prostate cancer (PCa).

MATERIALS AND METHODS: 157 patients with clinically localised PCa with a PSA < 10 ng/ mL and a negative DRE diagnosed on the first (12 samples, Group A) or second (18 samples, Group B) PB were enrolled at our institution. All patients underwent mp-MRI with T2-weighted images, diffusion-weighted imaging, dynamic contrast enhanced-MRI prior to RP. A map of comparison describing each positive biopsy sample was created for each patient, with each tumor focus shown on the MRI and each lesion present on the definitive histological examination in order to compare tumor detection and location. The sensitivity of mp-MRI and PB for diagnosis was compared using Student's t-test. The ability of the two exams to detect the prevalence of Gleason pattern 4 in the identified lesions was compared using a chi-square test.

RESULTS: Overall sensitivity of PB and mp-MRI to identify tumor lesion was 59.4% and 78.9%, respectively (p< 0.0001). PB missed 144/355 lesions, 59 of which (16.6%) were significant. mp-MRI missed 75/355 lesions, 12 of which (3.4%) were significant. No lesions with a GS ≥8 were missed. Sensitivity of PB and mp-MRI to detect the prevalence of Gleason pattern 4 was 88.2% and 97.4%, respectively.

CONCLUSIONS: mp-MRI seems to identify more tumor lesions than PB and to provide more information concerning tumor characteristics.

Written by:
Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Regge D.   Are you the author?
Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy; Radiology Unit Institute for Cancer Research and Treatment, Candiolo, Turin, Italy.

Reference: Int Braz J Urol. 2015 Jan-Feb;41(1):124-33.
doi: 10.1590/S1677-5538.IBJU.2015.01.17


PubMed Abstract
PMID: 25928518

UroToday.com Prostate Cancer Section